MedTrace Logo

Reversal of Complete Heart Block With Aminophylline in Inferior Wall Myocardial Infarction Patients

NCT05666219 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2025-05-25

No results posted yet for this study

Summary

In this study, the investigator will evaluate the rate of reversal of complete heart block with aminophylline in atropine resistant patients with inferior wall myocardial infarction (MI)

Conditions

  • Complete Heart Block
  • Inferior Wall Myocardial Infarction

Interventions

DRUG

Aminophylline Injection

Injection Aminophylline IV 240 mg will be given over 10 minutes. After 1 hour, Aminophylline 240 mg second dose will be given over 10 minutes.

Sponsors & Collaborators

  • National Institute of Cardiovascular Diseases, Pakistan

    lead OTHER

Principal Investigators

  • Azam Shafquat, MD · National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-19
Primary Completion
2023-12-18
Completion
2025-01-17
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05666219 on ClinicalTrials.gov